Pharmaceutical

Sanofi backs development of Graviton’s treatments for serious diseases

Graviton Bioscience has secured a strategic investment from Sanofi to propel the development of ROCK2 inhibitors for serious diseases.

Feb 2, 2024 - 18:00
Sanofi backs development of Graviton’s treatments for serious diseases
Graviton Bioscience has secured a strategic investment from Sanofi to propel the development of ROCK2 inhibitors for serious diseases.
Read the original article

Tags:

Previous Article

Biosyngen’s liver cancer therapy receives fast track designation

Next Article

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?

STAT+: Hemophilia gene therapies arrived after 40 years...

Mar 13, 2024

STAT+: The FDA is testing new nutrition labels on the front of food packages

STAT+: The FDA is testing new nutrition labels on the f...

Jun 20, 2023

Medicare Advantage’s 33 million club

Medicare Advantage’s 33 million club

Feb 21, 2024